Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
Ontology highlight
ABSTRACT: Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket. Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members. We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clinical stage EGFR inhibitors such as CI-1033. This cross-reactivity may have significant clinical implications.
SUBMITTER: Hur W
PROVIDER: S-EPMC2610413 | biostudies-literature | 2008 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA